J. Goldman & Co’s vTv Therapeutics VTVT Stock Holding History

J. Goldman & Co’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-650	Closed	-$106K	–	468
2018 Q1	$106K	Buy	+650	New	+$159K	﹤0.01%	328

Other funds holding VTVT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

J. Goldman & Co's VTVT Position: Q2 2018 in Review

J. Goldman & Co sold out of vTv Therapeutics (VTVT) in Q2 2018, closing a stake of 650 shares — an estimated $106K sold.

J. Goldman & Co first reported a position in VTVT in Q1 2018 and held it in 1 quarter. The position peaked at $106K in Q1 2018. 27 funds tracked by Wall St. Rank hold VTVT as of Q2 2018.

J. Goldman & Co reported no remaining vTv Therapeutics position as of Q2 2018 after selling out during the quarter.
J. Goldman & Co sold 650 vTv Therapeutics shares in Q2 2018, an estimated $106K.
J. Goldman & Co first reported a position in vTv Therapeutics in Q1 2018 and held it in 1 quarter.
J. Goldman & Co's vTv Therapeutics position peaked at $106K in Q1 2018.
27 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2018.

Based on J. Goldman & Co's 13F filing for Q2 2018, filed 14 Aug 2018.